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ABSTRACT 
Chronic myeloid leukaemia (CML) is caused by the acquisition of the tyrosine 
kinase BCR-ABL1 in a haemopoietic stem cell (HSC), transforming it into a 
leukaemic stem cell (LSC) that self-renews, proliferates and differentiates to give 
rise to a myeloproliferative disease. While tyrosine kinase inhibitors (TKI) that target 
the kinase activity of BCR-ABL1 have transformed CML from a once fatal disease 
to a manageable one for the vast majority of patients, only ~10% of those who 
present in chronic phase (CP) can discontinue TKI treatment and maintain a 
therapy-free remission. Strong evidence now shows that CML LSC are resistant to 
the effects of TKIs and they persist in all patients on long-term therapy, where they 
may promote acquired TKI resistance, drive relapse or disease progression and 
inevitably represent a bottleneck to cure. Since their discovery in patients almost 
two decades ago, CML LSC have become a well-recognised exemplar of the 
cancer stem cell and have been characterised extensively with the aim of 
developing new curative therapeutic approaches based on LSC eradication. This 
review summarises our current understanding of many of the pathways and 
mechanisms that promote the survival of the CP CML LSC and how they can be a 
source of new gene coding mutations that impact in the clinic. We also review 
recent pre-clinical approaches that show promise to eradicate the LSC, and future 
challenges on the path to cure.  
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CML: THE CLASSIC STEM CELL DISEASE 
Chronic myeloid leukaemia (CML) is a classic example of a stem cell cancer and 
arises when the t9;22 translocation (the Philadelphia chromosome)1-3 occurs in a 
haemopoietic stem cell (HSC). This event results in the constitutive expression of 
the fusion tyrosine kinase BCR-ABL1, transforming the HSC into the CML stem cell 
(referred to here as the leukaemic stem cell or LSC) which then gives rise to a 
clonal myeloproliferative disease. Early evidence regarding the HSC origins of CML 
came from observations that transfusion of peripheral blood cells from CML patients 
into severely neutropenic recipients resulted in temporary homologous BM 
engraftment and Ph+ progeny in the blood4. This was later explained by the 
presence of high numbers of mobilised LSC in the peripheral blood of chronic 
phase (CP) CML patients5. A possible haemopoietic progenitor origin of CML was 
ruled out when BCR-ABL1 expression in murine haemopoietic progenitors failed to 
confer self-renewal capabilities to BCR-ABL1+ cells, and these cells failed to induce 
leukaemia in mice6. Until very recently, BCR-ABL1 expression was considered 
sufficient to cause a CML-like disease in mouse models using retrovirus 
transduction or transgene insertional mutagenesis to express the oncogene in 
LSC7-9. However, issues with BCR-ABL1 copy number, high oncogene expression 
and/or secondary mutations arising by retroviral or transgene insertional 
mutagenesis or genomic instability could theoretically contribute to 
leukaemogenesis. In a recent knock-in model, a single copy of BCR-ABL1 
expressed from the endogenous BCR locus was able to confer enhanced BM 
engraftment, however this model was unable to induce leukaemia10.  
Whilst the cell of origin of CML is generally accepted to be the HSC, several studies 
implicate an HSC-precursor cell – the multipotent haemangioblast that gives rise to 
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both haemopoietic and endothelial cells. The BCR-ABL1 fusion can be detected in 
endothelial cells obtained from BM and peripheral blood of CML patients at varying 
frequencies11,12. These cells show altered intra-cellular signalling and protein 
expression that may affect crosstalk between LSC and the bone marrow 
microenvironment (BMM), alter immune-modulation and LSC exit from quiescence 
into proliferation13,14. Collectively these data suggest that the acquisition of BCR-
ABL1 in the haemangioblast may contribute to both malignant haemopoiesis and 
endotheliopoiesis.  
THE NATURAL HISTORY OF CML 
CML is a rare stem cell disease with an annual incidence of 1-2 cases per 
100,000 individuals peaking in the sixth and seventh decades of life15. Data derived 
from atomic bomb survivors16 suggest that following a latent period of some 7 
years, the natural history of CML is for 85-90% of cases to present in CP, but to 
progress to accelerated phase (AP) and then to either myeloid or lymphoid blast 
crisis (BC) over a 5 year time frame17. However, the mechanism of disease 
progression is complex and disease behaviour is highly variable for individual 
patients, with some progressing within a few months and others remaining in stable 
CP for up to 20 years. This heterogeneity between patients may relate to the 
mutations subsequently acquired in the BCR-ABL1 clone18, variations in gene 
expression patterns between patients19, or the subtype of HSC in which BCR-ABL1 
is first expressed - with recent evidence delineating multiple HSC subsets defined 
by variably fixed lineage potentialities, transcriptional profiles and phenotypes20-23. 
Furthermore, intriguing work on pre-leukaemia24,25 and the detection of BCR-ABL1 
in blood cells of normal individuals26,27 presents the possibility that heterogeneity 
could also be driven by mutations acquired before or after BCR-ABL1, or other 
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factors such as deregulation and skewing of lineage specification, clonal 
haemopoiesis, DNA damage, activation of inflammatory responses, and epigenetic 
alterations, all of which occur in haemopoiesis during aging28,29. Some, or all, of 
these factors may also be required for, or contribute to, disease development in 
mouse models of CML. 
LSC PERSISTENCE: A BOTTLENECK TO CURE 
The introduction of a potent BCR-ABL1 tyrosine kinase inhibitor (TKI), imatinib, 
almost two decades ago, followed by subsequent generations of TKI (dasatinib, 
nilotinib, bosutinib, ponatinib) has transformed the management of CML30,31. What 
was once a universally fatal disorder, unless treated with an allogeneic transplant, 
is now well controlled in the outpatient setting and overall survival has improved 
significantly (http://seer.cancer.gov/statfacts/html/cmyl.html) with the majority of 
patients requiring life-long TKI. In keeping with disease heterogeneity, patient 
responses to TKI are also variable. The majority of cases (50-70%) achieve major 
molecular response (MMR) where BCR-ABL1 levels detectable by quantitative PCR 
(qPCR) in the blood show a 3 log10 fold reduction, i.e., 0.1%, compared to a 
standardised baseline (reviewed elsewhere32). However, patient to patient variation 
in leukaemic cell blood counts at diagnosis, and variations in BCR-ABL1 expression 
between early and late stages of cell differentiation can often confound these 
interpretations. Approximately 10-20% of all patients develop even deeper 
molecular responses triggering dose de-escalation and discontinuation/stopping 
trials (STIM, TWISTER, DADI), where 50% of patients relapse within 12 
months33,34. When CP relapse occurs, the doubling time (≈ 9 days) for increasing 
disease burden mirrors the CML disease at diagnosis35. A quarter of CP patients 
fail TKI therapy36, and approximately half of these cases can be explained by BCR-
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ABL1 kinase domain mutations32,37 but the reason for failure in the remaining 
patients is unclear. 
Ironically, the earliest evidence of CML LSC38 pre-dated the introduction of TKI and 
this was followed by definitive evidence of a deeply, but reversibly, quiescent 
subpopulation of leukaemic cells in patients with CML39. In the subsequent years, 
the consensus view has emerged that virtually all CP patients on TKI therapy and in 
MMR are not cured of CML and show signs of residual disease burden due to the 
presence of LSC in the BM (termed “LSC persistence”). In a typical cohort of 100 
CP CML patients who undertake TKI therapy over a 5 year period, almost two-
thirds of them will have this “LSC persistence” phenotype (Figure 1). Researchers 
have consistently detected BCR-ABL1+ primitive cells in the BM of TKI-treated 
patients in MMR which are capable of growth in colony forming cell (CFC) and long-
term culture initiation cell (LTC-IC) assays, even in patients in deep molecular 
response with no detectable BCR-ABL1 transcripts by qPCR40-43. The most recent 
of these studies have shown that although LSC are not always detectable in cases 
of very deep molecular response, most likely due to technical limitations, some 
patients with no detectable LSC can subsequently relapse after TKI 
discontinuation43. Others have shown that the LSC that persist in patients in MMR 
express BCR-ABL1 at lower levels than LSC at the point of diagnosis. Furthermore, 
murine BM cells engineered to express low levels of BCR-ABL1 levels were far less 
sensitive to imatinib, while those expressing higher levels were prone to de novo 
mutations44. These findings point to LSC persistence as a “low mutator” phenotype, 
perhaps explaining why the majority of these patients do not develop drug 
resistance or progress to BC. The eradication of the LSC remains a challenge in the 
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majority of CML patients, a significant bottleneck to cure, and an area of intensive 
research.  
GENERAL FEATURES OF THE LSC 
At time of CP diagnosis, BCR-ABL1- cells co-exist with BCR-ABL1+ cells and 
enriched CD34+ populations require dual-fluorescent in situ hybridisation (D-FISH) 
to determine the proportion of cells that carry the Ph+ (usually >90% BCR-ABL1+). 
The more primitive LSC fraction can be purified by fluorescence-activated cell 
sorting (FACS) in a variety of ways, giving rise to overlapping, primitive, quiescent 
populations (Figure 2). Phenotypically and functionally, we define the CP CML LSC 
as those primitive stem/progenitor cells that show a higher capacity to engraft in 
immunocompromised mice than bulk CD34+ cells45, have stem cell properties (self-
renewal), are resistant to apoptosis46,47, are prone to genomic instability48,49 and 
have impaired DNA damage responses50-52. Since BCR-ABL1 drives survival and 
proliferation, it is somewhat of a paradox that CML LSC express BCR-ABL1 but can 
also be quiescent39 – a feature which may enable them to become refractory to TKI-
induced apoptosis. However, TKI also exert a potent anti-proliferative effect on CML 
CD34+ cells and LSC to induce quiescence46,53 and subsequent evidence has 
shown that TKI exert additional effects to subvert a number of pathways to promote 
survival (see below).  
BCR-ABL1 KINASE INDEPENDENT SURVIVAL  
To understand why LSC were refractory to the effects of TKI, we exposed CML 
CD34+ cells to high concentrations of dasatinib for 12 days, and subjected them, in 
parallel, to BCR-ABL1 knockdown. These in vitro studies were complemented in 
vivo using the inducible transgenic SCL-tTA/BCR-ABL model9. BCR-ABL1 
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expression was induced in mice to lead to the development of CML-like disease, 
then switched off to determine whether the LSC population required BCR-ABL1 for 
survival, and then induced for a second time to see whether the LSC were still 
functional and could again drive the development of CML-like disease. In the in vitro 
studies, functional BCR-ABL1+ LSC persisted in culture despite evidence for 
complete kinase inhibition and significant BCR-ABL1 knock-down. In the mouse 
model, CML-like disease re-occurred following the second induction of BCR-ABL1. 
This work demonstrated that LSC survival is not dependent on BCR-ABL1 kinase 
activity54 and suggested that BCR-ABL1 may have non-kinase mediated functions 
that modulate signalling pathways to promote LSC survival. These conclusions 
were further supported by others who used imatinib to fully inhibit BCR-ABL1 
kinase activity in both LSC and quiescent cells55. Taken together, these studies 
concluded that CML LSC were not “oncogene-addicted” and that targeting of BCR-
ABL1 kinase activity alone would not eliminate them. Furthermore, this work has led 
investigators worldwide to search for LSC selective, BCR-ABL1 kinase independent 
targets and pathways that might offer potential for improved targeting of LSC in 
CML. To date, a number of mechanisms, pathways and drug-able targets have 
been proposed to contribute to the TKI-resistant LSC phenotype (Figures 2-3, 
Tables 1-2). 
PI3K/AKT/FOXO SIGNALLING  
BCR-ABL1 has been shown to up-regulate PI3K/AKT signalling and AKT-mediated 
phosphorylation of FOXO transcription factors results in their cytoplasmic 
localisation where they are inactive (Figure 2). One important consequence of TKI 
exposure is inhibition of BCR-ABL1 and down-regulation of PI3K/AKT signalling in 
the LSC (kinase dependent), leading in turn to re-localisation of FOXO1 and 
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FOXO3a from the cytoplasm to the nucleus, where they modulate expression of 
CCND1, ATM, CDKN1C, and BCL6 causing a G1 arrest56,57 and may fuel an anti-
apoptotic phenotype. The transcriptional repressor BCL6, a FOXO3A target, is 
likely to play an important role in this process by repressing the tumour suppressors 
p53 and ARF. In this respect, TKI exposure permits FOXO3A-mediated up-
regulation of BCL6 resulting in a protective, pro-survival effect. Others have shown 
that the PI3K signalling axis in LSC is also under the control of TGFβ signalling 
(kinase independent) and blocking this pathway reversed the effects of FOXO 
nuclear translocation58,59. However, the precise mechanism of how this occurs is 
not fully understood and may not to be completely cell-autonomous. 
HEDGEHOG SIGNALLING  
Several studies have implicated the hedgehog pathway in the maintenance (self-
renewal) and proliferation of the LSC60-62, where Smoothened (SMO) is a critical 
mediator. Hedgehog binding to Patched (PTCH) activates SMO which in turn 
activates the transcription factor GLI1. This leads to reductions of NUMB 
expression and increased MDM2-mediated degradation of the p53 protein (Figure 
2). This would have the effect of suppressing apoptotic responses and/or cell cycle 
arrest through repression of p53 targets. SMO deletion or pharmacological 
inhibition in mouse models of CML blocked this pathway and led to loss of LSC60,61. 
However, TKI treatment alone was unable to block this pathway, suggesting that 
hedgehog signalling was kinase independent. More recently, similar results were 
obtained using SMO inhibitors in human CML samples in vitro and in vivo using 
xenografts in immunocompromised NOD scid gamma (NSG) mice62. 
CANONICAL AND NON-CANONICAL WNT SIGNALLING  
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β-catenin is a central mediator of both canonical and non-Wnt signalling and has a 
dual role in regulating cell-to-cell contact through tight junctions and acting as a 
transcriptional regulator when translocated to the nucleus (Figure 2). In the absence 
of Wnt signalling, cytoplasmic β-catenin is ultimately phosphorylated by GSK3β and 
targeted for degradation by an axin-mediated multimeric complex. Nuclear β-
catenin is required for self-renewal and survival of normal HSC63, and it therefore 
not surprising that it has also been shown to be a key mediator of LSC survival. 
Loss of β-catenin in a murine model of CML impaired the development of the 
disease by inhibiting LSC self-renewal64, and genetic and pharmacological inhibition 
of β-catenin activity synergised with TKI to target the loss of LSC65. Several 
alternative Wnt-regulated pathways have been implicated in CML LSC. TKI 
exposure induced the up-regulation of CD70 ligand-induced CD27 signalling66,67 
resulting in β-catenin nuclear translocation and activation of Wnt target genes, 
including NOTCH, and c-MYC (kinase dependent). TKI exposure also induces a 
non-canonical Wnt signalling mediated through NFAT signalling which reduces 
levels of the pro-survival cytokine IL-468 (kinase dependent). Fatty acid metabolism 
was demonstrated to be important in LSC when arachidonate 5-lipoxygenase, 
encoded by ALOX5 -  was shown to be up-regulated in LSC in a kinase 
independent manner69 where it is thought to regulate β-catenin levels. Inhibition of 
ALOX5, through genetic deletion or by pharmacological inhibition in mouse models, 
targeted the loss of LSC, implicating this component as an important mediator of 
LSC survival. 
JAK/STAT SIGNALLING 
The Janus kinases (JAK) family of intracellular non-receptor kinases play important 
roles in regulating cytokine-mediated signal transduction via the JAK/STAT pathway 
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(Figure 2). Activation of the signal transducer and activation of transcription 5 
(STAT5) was demonstrated in primary CML and CML cell lines twenty years ago70 
and this involves its phosphorylation and translocation to the nucleus where it 
regulates transcription. Subsequent evidence has also shown that a single null 
mutation in the STAT5a isoform can attenuate CML-like disease in mouse models71 
and knockdown can impair Ph+ myeloid colony formation from CML patient 
samples72. Modulating JAK2 activity in human and mouse cell lines reduces BCR-
ABL1 and STAT5 signalling73, and pharmacological inhibition using ruxolitinib 
resulted in the loss of LSC both in vitro and in vivo74, implicating JAK2 as an 
upstream mediator of a CML JAK/STAT signalling cascade in LSC. However, BCR-
ABL1 has also been implicated in the direct activation of STAT575 (kinase 
dependent), suggesting that JAK2 may not be necessary for CML disease 
maintenance. Furthermore, the re-activation of the tumour suppressor and serine-
threonine phosphatase PP2A, through either knockdown or pharmacological 
inhibition of its repressor SET, has been shown to inhibit BCR-ABL1 and STAT5 
activation in CML BC76. The scenario, however, is different in LSC, where BCR-
ABL1 exerts kinase independent roles to recruit JAK2 to modulate JAK/STAT 
signalling77,78 (see also below). Activation of STAT3 has also been implicated in the 
JAK/STAT cascade, where it exerts a protective effect on CML cells upon exposure 
to TKI79. Inhibition of STAT3 in combination with TKI induced synthetic lethality to 
target the loss of LSC80.  
GENOMIC INSTABILITY, DNA DAMAGE AND REPAIR  
Whether TKI-induced quiescence contributes to LSC persistence in patients is still 
an open question. Two possible beneficial consequences of TKI treatment would be 
to reduce the turnover and expansion of LSC in patients and enhance a “low 
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mutator” phenotype44. However, a more cautionary interpretation of these possible 
benefits has come from the examination of the mechanisms and pathways that 
contribute to genomic instability in LSC. BCR-ABL1 kinase activity leads to 
increased levels of reactive oxygen species (ROS)48,49,81, including H2O2, and these 
lead to oxidative DNA damage, including point mutations and double stranded 
breaks (DSB). In this regard, the RAC2 GTPase has been shown to alter the 
function of the mitochondrial respiratory chain complex (MRC-cIII) to generate ROS 
and DNA damage in LSC, as evidenced by the accumulation of chromosomal 
aberrations and clinically-relevant BRC-ABL1 kinase domain mutations49. This 
effect was also observed under hypoxia, the conditions that LSC are exposed to in 
the BM microenvironment, and during exposure to TKI where RAC2 levels were 
unaffected, thus demonstrating a kinase independent pathway. Inhibition of RAC2 
or disruption of the MRC-cIII reduced the level of genomic instability. Similarly, high 
ROS levels and associated genomic damage were re-capitulated using the 
transgenic SCL-tTA/BCR-ABL model48 where both BCR-ABL1 kinase domain 
mutations and various base pair additions/deletions in genes linked to progression 
to BC were identified in LSC in both TKI-naïve and TKI-treated mice. Evidence as 
to why such DNA damage is tolerated in LSC has also emerged. BCR-ABL1 can 
inhibit mismatch repair to protect cells from apoptosis50, and can stimulate single-
strand annealing, homologous recombination repair (HRR) and non-homologous 
end-joining, all of which are error-prone in BCR-ABL1 expressing cells52,81. 
Furthermore, LSC are dependent on the alternative RAD52-RAD51 pathway of 
HRR to deal with DSB rather than BRCA1/2-RAD51, due to the kinase independent 
down-regulation of BRCA182. While we are unable to reconcile these data with a 
“low-mutator” phenotype44, they point to the LSC as a potent source of clinically 
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relevant mutations, and also argue that CML is constantly evolving at the molecular 
level even in CP, countering the clinical view that it is a disease of 3 distinct phases. 
THE LSC BONE MARROW MICROENVIRONMENT 
While the pathways described above have ostensibly been studied as primarily cell-
intrinsic or cell-autonomous, it is likely that some, if not all, of them are regulated 
through interactions between the CML LSC and the BMM - and a number of these 
interactions have been identified (Figure 3, Table 2), some of which mediate TKI 
resistance.  
LSC adhesion within the BMM is likely to contribute to homing and lodgement – 
critical steps in LSC engraftment subsequent to transplantation. CD44, expressed 
on LSC, are ligands for e-selectins and lack of CD44 reduced homing and 
engraftment of LSC83. Similarly, a critical role for selectins and their ligands in 
engraftment has also been shown84 and e-selectins can be blocked 
pharmacologically to reduce the number of LSC. The lectin GAL-3 mediates 
resistance to TKI through binding β-galactosides on stromal cells and over-
expression activated AKT signalling and increased lodgement of LSC in the BM85. 
β1-integrins mediate adhesion of LSC to BM stromal cells, a process likely to be 
regulated by interferon α86,87. TKI-induced up-regulation of N-cadherin in LSC, and 
adhesion to mesenchymal stem cells led to increased canonical Wnt signalling and 
protection of the LSC from apoptosis88. The CXCL12 ligand and its receptor CXCR4 
has been linked to intracellular LYN signalling in LSC89, and the CXCL12/CXCR4 
axis is regulated through CXCL12 cleavage by CD2690. Reduced homing capacity 
of LSC has also been attributed to alterations of the CXCL12/CXCR4 signalling 
pathway as a result of increased granulocyte-colony stimulating factor (G-CSF) 
15 
 
levels which conferred a selective growth disadvantage to normal HSC91. LSC also 
exert other molecular and phenotypic effects on HSC through extrinsic IL-6 
signalling in the CML BMM92,93. Indeed, a variety of ligand-receptor mediated 
signalling pathways regulate CML LSC in the BMM (Figure 3, Table 2).  
It is likely that LSC also avoid eradication by modulation of host immune 
surveillance in the BMM (reviewed in detail elsewhere94). In this respect, cytotoxic T 
lymphocytes (CTLs) are unable to elicit an appropriate immune response against 
CML cells through CTL exhaustion - and this is believed to be mediated by the 
interaction of the PD-1 receptor expressed on CTLs with its inhibitory ligand PD-L1 
expressed on CML cells. PD-L1 is expressed on patient derived CML cells95 and on 
LSC in mouse models of CML96. Blockade of the PD-1/PD-L1 interaction in 
combination with T-cell immunotherapy was able to trigger the loss of LSC, and 
prevent development of CML-like disease96. Our recent work has demonstrated that 
cytokine-mediated downregulation of MHC-II expression may be an alternative way 
that LSC evade immune surveillance – and treatment with ruxolitinib or interferon 
gamma (IFNγ) can reverse this effect in vitro and enhance proliferation of 
responder CD4+CD69+ T cells in mixed lymphocyte reactions97. These examples 
represent exciting areas of research that could lead to new immune therapy-based 
therapeutic approaches.  
NEW THERAPIES TO TARGET LSC: RECENT APPROACHES 
The many examples summarised above illustrate the scope of potentially drug-able 
targets that have been identified in CML to eradicate LSC (Tables 1-2). 
Disappointingly, drugs against these targets have yet to be implemented in the 
clinic as standard of care. In the past 3-4 years, additional drug-able targets and 
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pathway have been identified, while others previously identified have been further 
elaborated in pre-clinical studies (Figure 4). Our analysis of global proteomics and 
transcriptomics in drug-naïve primary patient material (bulk CD34+ cells and LSC) 
pointed towards a dependency of CML cells on a p53 and c-MYC regulated 
network98. This provided a rationale to use a combination of MDM2 and BET 
inhibitors (MDM2i, BETi respectively) to target the synergistic eradication of LSC 
through up-regulation of the p53 apoptotic pathway and down-regulation of c-MYC 
by both drugs (Figure 4A). Given that BETi acts generally as a transcriptional 
repressor, how its effects lead to up-regulation of apoptosis in CML LSC is not fully 
understood, although this appears to be a common phenomenon of BETi in pre-
clinical cancer studies99. We have also used global epigenetic and transcriptomic 
analysis of drug-naïve primary patient material to reveal that mis-regulation of the 
PRC2 complex (including kinase independent down-regulation of EZH1 in LSC) 
results in the functional dependency of LSC on EZH2 and its biochemical readout 
H3K27me3. Using murine models, others have also reported that CML LSC are 
dependent on EZH2100. Combining an EZH2 inhibitor (EZH2i) with TKI was highly 
effective at eradicating the LSC population101. Our data supports a model whereby 
apoptosis is induced in CML LSC through the up-regulation of EZH2 targets 
upstream of p53 (such as ARF), which could lead to increased p53 levels, or 
through up-regulation of p53 target genes directly which are normally repressed by 
EZH2 activity (Figure 4A).  
Two groups have shown that activators of the peroxisome proliferator-activated 
receptor gamma (PPARγ) have increased anti-leukaemic activities in combination 
with TKI102,103. Quiescence of LSCs is regulated by a pathway involving the receptor 
PPARγ, STAT5, HIF2α, and CITED2 - a master regulator of blood stem cell 
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quiescence (Figure 4B). Activators of PPARγ result in transcriptional down-
regulation of STAT5, whilst TKI block phosphorylation of STAT5 – the combined 
effects of both drugs significantly down-regulating this pathway and caused LSC to 
exit quiescence where they were eradicated by TKI104. Recently, EZH2 has been 
shown to be activated by STAT5 in CML cells105 suggesting possible cross-talk 
between the effects of PPARy activators and those of EZH2i. 
The TKI-mediated up-regulation of CD70 has been further examined to provide a 
clear rationale for inhibiting non-canonical Wnt/β-catenin signalling in LSC67. Upon 
exposure to TKI, the microRNA miR-29 is down-regulated – the consequence of 
which is up-regulation of CD70 through the opposing roles of miR-29 on SP1 and 
DNMT1a regulation (Figure 4C). Thus, antibody-based blockade of the interaction 
between CD70 and CD27 resulted in a potent loss of LSC in the presence of TKI67. 
Two other routes for inhibiting β-catenin signalling in LSC have also recently been 
deduced. In the first, BCR-ABL1 interacts directly with JAK2 in a kinase 
independent manner to activate a JAK2/β-catenin survival/self-renewal pathway 
that results in inhibition of PP2A and activation of β-catenin (Figure 4D). Use of 
PP2A activating drugs (PADs) reversed these effects resulting in GSKβ-dependent 
degradation of β-catenin and eradication of LSC77. In the second, another enzyme 
in fatty acid metabolism arachidonate 15-lipoxygenase (15-LO encoded by 
ALOX15) has been implicated in the kinase independent up-regulation of β-catenin, 
although the exact mechanism is unclear. However, pharmacological inhibition of 
15-LO in combination with nilotinib on human LSCs in vitro appeared synergistic106. 
In addition, the p-selectin SELP appears to be a key down-stream target of 15-LO, 
which is normally repressed to promote LSC survival. Further pre-clinical studies 
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and mechanistic studies are required to provide a clearer rationale for taking 15-LO 
inhibitors into clinical trials as has been done with zileuton which inhibits 5-LO69. 
FUTURE CHALLENGES 
We know little about how TKI-resistant LSC clones evolve in patients in MMR and 
the degree of intra- and inter- patient heterogeneity that is likely to exist – not only 
at the DNA level, but also with respect to the many pathways that we have 
identified by studying diagnostic drug-naïve LSC for many years. This is because (i) 
the TKI-resistant LSC are extremely rare in the BM of these CML patients, and (ii) 
the LSC cannot be selectively isolated from the normal HSC that reconstitute 
normal haemopoiesis in the BM subsequent to TKI therapy. Surrogate in vivo 
analysis has also been problematic since the majority of CML primary samples do 
not engraft well in commonly used immunodeficient mice strains. These issues 
most likely underpin the failure of many promising new drugs to deliver results in 
clinical trials. However, recent advances in tracking individual normal and malignant 
clones in xenograft models using bar-coding21,107, the development of humanised 
xenograft models108, an explosion of single cells technologies20,109, and the 
identification of a number of leukaemia-specific cell surface markers, make the 
analysis of individual LSC or LSC clones much more accessible. Furthermore, 
several groups have identified markers that discriminate LSC from HSC (CD2690, 
IL-1RAP110, CD25111 and CD93112) but how these will perform in samples from 
patients in MMR has yet to be determined. For those of us that are intent on curing 
CML, this new era of game-changing technologies provides some tantalizing 
prospects that will enable us to finally stem the tide on drug-resistant LSC. 
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TABLES 
TARGET OR 
SURVIVAL 
FACTOR 
PATHWAY 
EXEMPLAR 
INHIBITORS/ 
ACTIVATORS 
REFERENCES 
CML CLINICAL 
TRIAL 
ALOX15 
β-catenin; PI3K/AKT 
signalling 
PD146176 Chen et al. 2014106  No 
ALOX5 
Wnt/β-catenin 
signalling 
zileuton Chen et al. 200969 Yes 
autophagy autophagy 
chloroquine;   
bafilomycin A1 
As2O3 
Bellodi et al. 2009113                  
Goussetis et al. 
2012114 
Karvela et al. 2016115 
Yes 
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BCL6 
PI3K/AKT/FOX3a/ 
BCL6 signalling 
RI-BPI Hurtz et al. 201156 No 
BLK 
MYC/PAX5/BLK/ 
CDKN1B signalling 
n.a. Zhang et al. 2012116 No 
CCN 
Wnt/Ca2+/NFAT 
signalling 
cyclosporin A Gregory et al. 201068 No 
CD25 JAK/STAT signalling BEZ235 
Sadovnik et al. 
2015111 
No 
CD70/CD27 
Wnt/β-catenin 
signalling 
αCD70 mAb Riether et al. 201567 No 
c-MYC  & 
TP53 
apoptosis CPI-203; RITA/RG7388 Abraham et al. 201698 No 
EZH2 
histone H3 K27 tri-
methylation 
GSK 343; GSK126;  
EPZ-6438 (tazemetostat) 
Scott et al. 2016101                              
Xie et al. 2016100 
No 
farnesyl 
transferases 
RAS signalling;         
protein farnesylation 
BMS-214662 Copland et al. 2008117 Yes 
FOX03A 
TGFβ/AKT/FOXO3a/ 
BCL6 signalling 
n.a. 
Pellicano et al. 201357                 
Naka et al. 201058 
No 
GSK3β 
Wnt/β-catenin 
signalling 
 SB216763 
Reddiconto et al. 
2012118 
No 
HDACs histone acetylation LBH589 Zhang et al. 2010119 Yes 
JAK2 JAK/STAT signalling ruxolitinib Gallipoli et al. 201474 Yes 
PML 
apoptosis; mTOR 
repression 
arsenic  trioxide (As2O3) Ito et al. 2008120 Yes 
PP2A 
JAK/STAT/β-catenin 
signalling 
1,9-dideoxy-forskolin; 
FTY720 
Neviani et al. 200576 
Neviani et al. 201377                
No 
PPARγ 
STAT5/HIF2α/ 
CITED2 
pioglitazone 
Prost et al. 2015102                  
Glodkowska-Mrowka 
et al. 2016103 
Yes 
RAD52 DNA repair 
RAD52 F79 peptide 
aptamer 
Cramer-Morales et al. 
201382 
No 
SIRT1 deacetylation of p53 tenovin-6 (TV-6) Li et al. 2012121 No 
SMO Hedgehog signalling cyclopamine; LDE225; 
Zhao et al.  200960                       
Dierks et al. 200861                      
Irvine et al. 201662 
Yes 
STAT3 JAK/STAT signalling BP-5087 Eiring et al. 201580 No 
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TGF-β RI, 
ALK5 
TGFβ/AKT/FOXO3a/ 
BCL6 signalling 
Ly364947; EW-7197 
Naka et al.  201058                         
Naka et al. 2016122 
No 
 
Table 1: Candidate therapeutic targets in CP CML LSCs. Column one: key 
survival factors/drug targets intrinsic to the LSC. Column two: the roles of these 
factors/targets in cellular pathways (if known or as proposed by investigators). 
Column three: exemplar compounds that have been identified as having potential 
therapeutic value for each factor/target or pathway (if known). Column four: 
references where the factors/targets were described. Column five: whether 
factors/targets or compounds have been evaluated in clinical trials that we know of. 
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TARGET OR 
SURVIVAL 
FACTOR 
PATHWAY 
EXEMPLAR 
INHIBITORS/ 
ACTIVATORS 
REFERENCES 
CML 
CLINICAL 
TRIAL 
β1-integrins 
cell adhesion; 
proliferation 
IFNα 
Bhatia et al. 199487                        
Bhatia et al. 199686 
Yes 
CD26 
CXCL12/CXCR4 
signalling 
glyptins Herrmann et al. 201490 No 
CD44 
e-selectin ligands; 
homing, 
engraftment 
n.a. Krause et al. 200683 No 
CXCR4 
CXCL12/CXCR4 
axis 
AMD3465; AMD3100; 
plerixafor 
Jin et al. 2008123                         
Weisberg et al. 2012124            
Dillmann et al. 2009125              
Vianello et al. 2010126 
Yes 
BMP2/4 BMP signalling n.a. Laperrousaz et al. 2013127 No 
GAL-3 
(Galectin-3) 
BM lodgement n.a. 
Yamamoto-Sugitani et al. 
201185 
No 
HIF1α hypoxia response n.a. 
Zhang et al. 2012128                                
Ng et al. 2014129 
No 
IFNα 
immune 
surveillance; 
cytokine-mediated 
proliferation  
interferon alfa-2a 
Preudhomme et al. 2010130                   
Burchert et al. 2010131 
Simonsson et al. 2011132 
Nicolini et al. 2015133 
Hjorth-Hansen et al. 
2016134 
Yes 
IL-1RAP/IL-1 
NFKβ/AKT 
signalling 
IL-1RAP mAb 
(mAb81.2) 
Jaras et al. 2010110                    
Ågerstam  et al. 2016135 
Zhang et al. 2016136 
Yes 
IL-6 
IL-6Rα signalling 
from the 
microenvironment 
αIL-6 mAb Welner et al. 201592 No 
LYN 
CXCR4/CXCL12 
signalling in lipid 
rafts 
methyl-beta-
cyclodextrin; PP2 
Tabe et al. 201289 No 
MHC-II/CIITA 
JAK/STAT 
signalling 
ruxolitinib, IFNγ  Tarafdar et al.97 Yes 
miR-126 exosomal transfer 2-O-Me-miR-126 Taverna et al. 2014137 No 
N-cadherins 
N-cadherin/ Wnt/   
β-catenin signalling 
ICG001 Zhang et al. 201388 No 
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JAGGED-1 Notch signalling n.a. Bowers et al. 2015138 No 
MPL 
JAK/STAT 
signalling; 
engraftment 
n.a. Zhang et al. 2016139 No 
PD-1/PD-L1 
immune 
surveillance  
αPD-L1 mAb 
αPD-1 mAb 
Mumprecht et al. 200995    
Riether et al. 201596            
Yes 
PIGF 
VEGF signalling: 
BM angiogenesis; 
proliferation; 
metabolism 
5D11D4 Schmidt et al. 2011140 No 
selectins 
BM homing; 
engraftment 
GMI-1271 
Krause et al. 201484  
Aggoune et al. 2014141 
No 
TGF-β1 
osteoblast → LSC 
TGFβ signalling 
parathyroid hormone 
(PTH) 
Krause et al. 2013142 No 
 
Table 2: Candidate therapeutic targets implicated in CP CML LSC/BMM 
interactions. Column one: key survival factors that act through LSC/BMM 
interactions. Column two: the roles of these survival factors in cellular pathways (if 
known or as proposed by investigators). Column three: exemplar compounds that 
have been identified as having potential therapeutic value for each target (if known). 
Column four: references where the targets were described. Column five: whether 
targets or compounds have been evaluated in clinical trials. 
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FIGURE LEGENDS 
Figure 1: The CP CML patients’ journey through TKI therapy for 5 years. The 
schematic shows the clinical outcome for a typical 100 CP CML patients with respect 
to response to imatinib over the course of 5 years, and the decision-tree leading to 
discontinuing TKI or switching to 2nd or 3rd generation TKI for various reasons. 
Outcomes were compiled based on data obtained from various sources31,143-146. By 
the end of year 5: twelve (12) (green segment of the pie chart) of these 100 patients 
will typically be off TKI and in therapy-free remission (TFR), more than a quarter (26) 
(red segment of the pie chart) will have failed TKI therapy (even after drug switching 
or through disease progression to AP or BC), and the majority (62) (amber segment 
of the pie chart) will remain on long-term TKI therapy but have residual disease due 
to LSC persistence in their BM.  
Figure 2: General features and critical pathways that contribute to CP CML LSC 
being quiescent, refractory to apoptosis and prone to DNA damage. Typically 
LSC represent 1-5% of the bulk CML CD34+ cells, are enriched by FACS as 
CD34+CD38-, and show more variable levels of Ph+ cells than bulk CML CD34+ cells. 
Some researchers also include Lin-/CD90+/CD45RA- cells as part of the CD34+CD38- 
LSC definition112. Other FACS approaches can also be used to isolate LSC which 
employ Hoechst, Pyronin Y and carboxyfluorescein succinimidyl ester (CFSE) 
intracellular staining in combination with CD34 to identify quiescent/undivided 
cells39,46,47,147. CD34+CD38- CML cells from patients at diagnosis which retain high 
levels of CFSE (CFSEmax) or are CD34+ and both Hoechstlo and Pyronin Ylo, and 
survive exposure to TKI, are often considered surrogate in vitro models for the TKI-
resistant cells that are found in patients with LSC persistence. The schematic 
diagram of the LSC shows key (but not exhaustive) pathways and components and 
whether the published evidence points to TKI-dependent (blue) or independent (olive 
green) mechanisms of regulation. Dotted lines denote translocation of components 
from the cytoplasm (light red) to the nucleus (white). ROS = reactive oxygen species. 
TK = tyrosine kinase. Activation and repression are denoted according to convention. 
Specific details of each pathway are described in the text. 
Figure 3: LSC survival signalling in the CP CML bone marrow 
microenvironment (BMM). The schematic diagram of the BMM shows key (but not 
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exhaustive) pathway components that mediate signalling between the LSC (light red) 
and other BMM cell types. HSC is shown in blue. OB = osteoblast cells (tan); CTL = 
cytotoxic T-cell (turquoise). Ligands involved in various signalling pathways are 
shown as small coloured spheres. IL-1/IL-1RAP regulates NFKβ signalling in LSC, 
and can be blocked using a monoclonal antibody to IL-1RAP135. MPL, the 
thrombopoietin (TPO) receptor, regulates JAK/STAT signalling and CML patients 
with high MPL expression on their LSC have reduced sensitivity to BCR-ABL1 kinase 
inhibition with TKI, but a higher sensitivity to JAK inhibitors139. Leukemic progenitor 
expansion is driven by exposure of LSC, overexpressing BMPR1B, to BMP2 and 
BMP4127.The CML BMM is also thought to over-express the NOTCH ligand 
JAGGED-1 implicating NOTCH signalling in LSC quiescence138. LSC stimulate the 
production of placental growth factor (PIGF) by BM stromal cells which works in a 
positive feedback loop to increase angiogenesis of the BM and promote CML cell 
proliferation through FLT1 (VEGFR1) signalling140. Stimulation of BM osteoblasts 
with parathyroid hormone (PTH) resulted in bone remodelling and production of 
TGFβ1, eradicated LSC by stimulating TGFβ signalling142 (the opposite effect to 
other reports of TGFβ signalling in LSC58,122). Similarly, others have shown that 
expansion of the osteoblast layer of the CML BMM can contribute to creating a 
hostile environment for HSC – and these effects are mediated by TPO, CCL3 and 
direct cell-cell interactions that alter TGFβ, NOTCH and pro-inflammatory signalling 
in the remodelled osteoblasts148. Other abbreviations are as described in the text. 
Other features are as described in Figures 2 and 3. 
Figure 4: Recent therapeutic approaches to target the eradication of CP CML 
LSC. A. Dual targeting of c-MYC and TP53 (p53) or combined treatment with TKI 
and EZH2 inhibitor (EZH2i)98,100,101. Both approaches converge on up-regulating p53-
mediated apoptosis through different mechanisms. BET and MDM2 inhibitors (BETi 
and MDM2i respectively) lead to synergistic repression of c-MYC transcription and 
up-regulation of p53 target genes. A dependency on EZH2 for LSC survival is 
accompanied by a TKI-independent down-regulation of EZH1. B. Inhibition of STAT5 
upstream of the HIF2α-CITED2 pathway that governs LSC quiescence. Combining a 
PPARγ activator (PPARγa) with TKI102,103 inhibits STAT5 transcription and STAT5 
phosphorylation respectively and down-regulates HIF2α-CITED2 leading to LSC exit 
from quiescence. C. Inhibition of non-canonical Wnt/β-catenin signalling mediated by 
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CD70/CD27. TKI up-regulates the Wnt/β-catenin pathway by inhibiting miR-29 
expression thus facilitating both increased CD70 expression and CD70/CD27 
receptor/ligand interaction. Treatment with a monoclonal antibody that blocks the 
CD70/CD27 interaction (αCD70) in a TKI background blocks the pathway66,67. D. 
Activation of PP2A to inhibit a novel CML network driven by JAK2-β-catenin 
signalling. PP2A activating drugs (PADs) disrupt the PP2A-SET interaction thereby 
allowing PP2A reactivation which inhibits BCR-ABL1 recruitment of JAK2 (TKI-
independent) and impairs β-catenin signalling through GSK-3β activation77. E. 
Inhibition of ALOX15 to inhibit β-catenin and PI3K/AKT signalling. Knockdown of 
ALOX15 or treatment with a 15-LO inhibitor (15-LOi) which blocks ALOX15 
enzymatic activity reduced LSC survival in association with reduced PI3K/AKT and 
β-catenin levels. This “kill” phenotype was rescued by loss of p-selectin (SELP), 
which is thought to negatively regulate LSC self-renewal and survival106. TK = 
tyrosine kinase. Activation and repression are denoted according to convention. Drug 
treatments are shown in yellow. Further details are described in the text. 




